Russ Lebovitz, MD, PhD | Venture Partner

Dr. Lebovitz is currently the CEO of Marval Biosciences, Inc., and the founder and Chairman of Imagnx, Inc., both DFJ Mercury portfolio companies.  Previously, Dr. Lebovitz was the President & CEO of C-sixty (acquired by Tego Biosciences) and the subsequent CEO of Tego Biosciences.  During the last decade, Dr. Lebovitz has managed global projects for a number of Fortune 100 technology companies including Royal Dutch Shell, Nextel, Cingular Wireless, Johnson & Johnson, Compaq Computer and JPMorganChase, as well as leading venture capital and investment banking firms. He has helped raise over $100 million for early and intermediate stage pharmaceutical and biomedical device companies.

Prior to his business activities, Dr. Lebovitz worked for over fifteen years as a successful senior scientist and research physician. He completed his undergraduate studies at the University of Michigan, and received his M.D. and Ph.D. degrees from Washington University in St. Louis. Dr. Lebovitz also served on the faculty of Baylor College of Medicine in Houston and The Fox Chase Cancer Center in Philadelphia.

Portfolio Company Focus

Marval Biosciences, Imagnx, Prolacta Biosciences